of the American Academy for the Advancement of Science. Clinical Development Program ADXS-HPV is in Phase 2 trials for HPV-associated diseases (cervical intraepithelial neoplasia (CIN), cervical cancer and HPV-associated head and neck cancer). In 2009 Advaxis published the results of the first Phase 1 trial with the first Lm-LLO based immunotherapy, ADXS-HPV in Vaccine (19 June 2009 / Volume 27, Issue 30). This study assessed side effects associated with increasing doses of ADXS-HPV in patients with metastatic, refractory, recurrent cervical cancer. Vaccine (19 June 2009 / Volume 27, Issue 30) This study demonstrated for the first time that a live-attenuated Lm-LLO based immunotherapy could be administered to human subjects. ADXS-HPV was well tolerated, and a maximum tolerated dose was established. 4/13 evaluable patients experienced increased survival and tumor shrinkage that merited further investigation. Veterinary Medicine Program Advaxis signed a CRADA (Cooperative Research And Development Agreement) with the Department of Homeland Security. The DHS will initially conduct a pilot “proof-of-concept” study in cattle investigating the safety of proprietary/patented Advaxis immunotherapies. Advaxis has begun a Phase 1 study with the University of Pennsylvania School of Veterinary Medicine to evaluate an Lm-LLO based immunotherapy in a Phase 1 study in canine osteosarcoma. References Biotechnology companies of the United States Companies based in Princeton, New Jersey Companies formerly listed on the Nasdaq Companies traded over-the-counter in the United States 2002 establishments in New Jersey Biotechnology companies established in 2002 Immunotherapy